The hemagglutinin-neuraminidase gene of Newcastle Disease Virus: A powerful molecular adjuvant for DNA anti-tumor vaccination. Aug 2010 - :1873-2518 [PMID:20709006] [Ni J] [Schirrmacher V] [Fournier P]
Activation of natural killer cells by newcastle disease virus hemagglutinin-neuraminidase. Jul 2009 - J. Virol.; 83(16):1098-5514 [PMID:19515783] [Jarahian M] [Watzl C] [Fournier P] [Arnold A] [Djandji D] [Zahedi S] [Cerwenka A] [Paschen A] [Schirrmacher V] [Momburg F]
Newcastle disease virus: a promising vector for viral therapy, immune therapy, and gene therapy of cancer. Jul 2009 - Methods Mol. Biol.; 542:1064-3745 [PMID:19565923] [Schirrmacher V] [Fournier P]
Treatment of advanced metastasized breast cancer with bone marrow-derived tumour-reactive memory T cells: a pilot clinical study. Apr 2009 - Cancer Immunol. Immunother.; 58(6):1432-0851 [PMID:18998129] [Schuetz F] [Ehlert K] [Ge Y] [Schneeweiss A] [Rom J] [Inzkirweli N] [Sohn C] [Schirrmacher V] [Beckhove P]
Expression of RIG-I, IRF3, IFN-beta and IRF7 determines resistance or susceptibility of cells to infection by Newcastle Disease Virus. Mar 2009 - Int. J. Oncol.; 34(4):1019-6439 [PMID:19287954] [Wilden H] [Fournier P] [Zawatzky R] [Schirrmacher V]
Cross-infection of tumor cells by contact with T lymphocytes loaded with Newcastle disease virus. Mar 2009 - Int. J. Oncol.; 34(4):1019-6439 [PMID:19287952] [Pfirschke C] [Schirrmacher V]
Efficiency of adjuvant active specific immunization with Newcastle disease virus modified tumor cells in colorectal cancer patients following resection of liver metastases: results of a prospective randomized trial. Oct 2008 - Cancer Immunol. Immunother.; 58(1):1432-0851 [PMID:18488223] [Schulze T] [Kemmner W] [Weitz J] [Wernecke KD] [Schirrmacher V] [Schlag PM]
Activation of human T cells by a tumor vaccine infected with recombinant Newcastle disease virus producing IL-2. Sep 2008 - Int. J. Oncol.; 33(4):1019-6439 [PMID:18813797] [Janke M] [Peeters B] [Zhao H] [de Leeuw O] [Moorman R] [Arnold A] [Ziouta Y] [Fournier P] [Schirrmacher V]
Recombinant Newcastle disease virus expressing human interleukin-2 serves as a potential candidate for tumor therapy. Jul 2008 - Virus Res.; 136(1-2):0168-1702 [PMID:18538434] [Zhao H] [Janke M] [Fournier P] [Schirrmacher V]
An effective tumor vaccine optimized for costimulation via bispecific and trispecific fusion proteins. Mar 2008 - Int. J. Oncol.; 32(4):1019-6439 [PMID:18360705] [Aigner M] [Janke M] [Lulei M] [Beckhove P] [Fournier P] [Schirrmacher V]
Recombinant Newcastle disease virus (NDV) with inserted gene coding for GM-CSF as a new vector for cancer immunogene therapy. Nov 2007 - Gene Ther.; 14(23):0969-7128 [PMID:17914407] [Janke M] [Peeters B] [de Leeuw O] [Moorman R] [Arnold A] [Fournier P] [Schirrmacher V]
Host mediated anti-tumor effect of oncolytic Newcastle disease virus after locoregional application. Oct 2007 - Int. J. Oncol.; 31(5):1019-6439 [PMID:17912426] [Apostolidis L] [Schirrmacher V] [Fournier P]
Tumor selective replication of Newcastle disease virus: association with defects of tumor cells in antiviral defence. Jun 2006 - Int. J. Cancer; 119(2):0020-7136 [PMID:16470838] [Fiola C] [Peeters B] [Fournier P] [Arnold A] [Bucur M] [Schirrmacher V]
A tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes. Dec 2005 - Int. J. Cancer; 118(3):0020-7136 [PMID:16108015] [Haas C] [Lulei M] [Fournier P] [Arnold A] [Schirrmacher V]
Tumor-targeted gene transfer in vivo via recombinant Newcastle disease virus modified by a bispecific fusion protein. Jul 2005 - Int. J. Oncol.; 27(2):1019-6439 [PMID:16010418] [Bian H] [Fournier P] [Peeters B] [Schirrmacher V]
